A Phase I Study of the Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 12 Nov 2018
Price : $35 *
At a glance
- Drugs VLX 600 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Vivolux
- 12 Nov 2018 Results published in the Investigational New Drugs
- 03 May 2018 Status changed from recruiting to discontinued.
- 26 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017.